Entering text into the input field will update the search result below

Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q1 2021 Results - Earnings Call Transcript

May 05, 2021 2:50 PM ETClovis Oncology, Inc. (CLVSQ)
SA Transcripts profile picture
SA Transcripts

Clovis Oncology, Inc. (CLVS) Q1 2021 Earnings Conference Call May 5, 2021 8:30 AM ET

Company Participants

Anna Sussman - Vice President of Investor Relations & Corporate Communications

Patrick Mahaffy - President & Chief Executive Officer

Thomas Harding - Chief Scientific Officer

Lindsey Rolfe - Chief Medical Officer

Dan Muehl - Chief Financial Officer

Conference Call Participants

Gavin Scott - JPMorgan

Ed White - H.C. Wainwright

Paul Choi - Goldman Sachs.

Andrew Berens - SVB Leerink

Joe Catanzaro - Piper Sandler

Tazeen Ahmad - Bank of America


Good day and thank you for standing by and welcome to the Clovis Oncology Quarter One Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions]

I would now like to hand the conference over to your speaker today Ms. Anna Sussman. Please go ahead.

Anna Sussman

Thank you, Polly. Good morning everyone. Welcome to the Clovis Oncology first quarter 2021 conference call. Thank you for joining us. You've likely seen this morning's news release. If not, it's available on our website at Clovisoncology.com.

As a reminder, this conference call is being recorded and webcast. Remarks may be accessed live on our website during the call and will be available in our archive for the next several weeks. Today's agenda includes the following. Patrick Mahaffy, our President and CEO will review the highlights of today's corporate update and Rubraca commercial progress. Then Dr. Thomas Harding our Chief Scientific Officer will review the FAP-2286 program and targeted radionuclide therapy development program.

Dr. Lindsey Rolfe, our Chief Medical Officer will discuss the anticipated clinical milestones for both Rubraca and lucitanib during 2021. And then Dan Muehl, our Chief Financial Officer will cover the

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.